Glenmark Pharmaceuticals launched Fabiflu on Saturday said it has launched antiviral drug Favipirivir, under the brand name Fabiflu, For the patients with moderate and mild Covid-19 with a price tag of 103 Rs per tablet.
This is a 200 mg tablet and we will get it with a strip of 34 Tablets and with an MRP of 3,500 Rs.
They have approved this tablet in India and will be available in all hospitals and retail stores.
It is a prescription based medicine and should be used strictly on advice of a doctor’s.
This firm received the manufacturing and also marketing approval from DCGI (Drug Controller general of India).
This drug will effectively reduce the pressure for doctors and will also be helpful for recovery of patients swiftly.
We started work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for COVID-19.
This is also an oral product and will be helpful even when hospitals cannot support the drastically growing numbers of Covid-19 Patients.
The approval also restricted use of resposible medication usage where every patient must have a signed and informed consent before treatment.
This medicine has shown 88 percent clinical improvement in mild to moderate Covid-19 Cases.
This Favipiravir has already been approved in Japan from 2014 to treat these kinds of Viruses.
There has been a record increase of cases in India in a single day with 14,516 cases . Please take care of yourself and stay safe.
Also Read :